AVENIO Tumor Tissue Analysis Kits

Overview

AVENIO Tumor Tissue Analysis Kits are a portfolio of three NGS assays that provide a simpler, optimized workflow for the detection of all four mutation classes from the DNA of formalin-fixed paraffin-embedded (FFPE) tissue samples.

The three AVENIO tissue assays contain matched panel content with the three corresponding AVENIO ctDNA liquid biopsy assays.

 

Features and Benefits of AVENIO Tumor Tissue Analysis Kits

  • Exactly-matched tissue and ctDNA panels (same genes, gene regions and hybrid-capture workflow) to facilitate concordance analysis 
  • All four mutation classes (SNVs, indels, fusions and CNVs) in a single DNA workflow with exceptional sensitivity and specificity1
  • 99% success rate for FFPE tissue samples that pass input QC testing using the AVENIO QC kit included with AVENIO tumor tissue assays
  • Flexibility to switch between tissue and plasma to support a variety of research applications
  • A streamlined, end-to-end workflow from extraction to analysis and reporting in 5 days
  • A turnkey solution that includes reagents, intuitive analysis and reporting to facilitate in-house adoption of high performance NGS oncology testing

Exceptional Performance





End-to-end workflow from extraction to analysis and reporting in five days





...

AVENIO Tumor Tissue Targeted Kit - Tumor Profiling

The AVENIO Tumor Tissue Targeted Kit is a 17 gene (81kb) pan-cancer assay that contains guideline-aligned biomarkers, including those identified by the U.S. National Comprehensive Cancer Network (NCCN).

Learn more
...

AVENIO Tumor Tissue Expanded Kit - Expanded Tumor Profiling

The AVENIO Tumor Tissue Expanded Kit is a 77 gene (192kb) pan-cancer assay that contains 17 genes in the NCCN and other guidelines, plus 60 emerging biomarkers investigated in clinical trials.

Learn more
...

AVENIO Tumor Tissue Surveillance Kit - Longitudinal Tumor Burden Monitoring

The AVENIO Tumor Tissue Surveillance Kit is a 197 gene (198kb) pan-cancer assay that contains 17 genes in the NCCN and other guidelines, and an additional 180 genes that are specially optimized for longitudinal monitoring of tumor burden and detection of minimal residual disease in lung cancer and colorectal cancer.

Learn more

References

  1. Data on file.
  2. National Comprehensive Cancer Network.  October 15, 2016.